Cargando…

Ketogenic diet ameliorates axonal defects and promotes myelination in Pelizaeus–Merzbacher disease

Pelizaeus–Merzbacher disease (PMD) is an untreatable and fatal leukodystrophy. In a model of PMD with perturbed blood–brain barrier integrity, cholesterol supplementation promotes myelin membrane growth. Here, we show that in contrast to the mouse model, dietary cholesterol in two PMD patients did n...

Descripción completa

Detalles Bibliográficos
Autores principales: Stumpf, Sina K., Berghoff, Stefan A., Trevisiol, Andrea, Spieth, Lena, Düking, Tim, Schneider, Lennart V., Schlaphoff, Lennart, Dreha-Kulaczewski, Steffi, Bley, Annette, Burfeind, Dinah, Kusch, Kathrin, Mitkovski, Miso, Ruhwedel, Torben, Guder, Philipp, Röhse, Heiko, Denecke, Jonas, Gärtner, Jutta, Möbius, Wiebke, Nave, Klaus-Armin, Saher, Gesine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570703/
https://www.ncbi.nlm.nih.gov/pubmed/30919030
http://dx.doi.org/10.1007/s00401-019-01985-2
Descripción
Sumario:Pelizaeus–Merzbacher disease (PMD) is an untreatable and fatal leukodystrophy. In a model of PMD with perturbed blood–brain barrier integrity, cholesterol supplementation promotes myelin membrane growth. Here, we show that in contrast to the mouse model, dietary cholesterol in two PMD patients did not lead to a major advancement of hypomyelination, potentially because the intact blood–brain barrier precludes its entry into the CNS. We therefore turned to a PMD mouse model with preserved blood–brain barrier integrity and show that a high-fat/low-carbohydrate ketogenic diet restored oligodendrocyte integrity and increased CNS myelination. This dietary intervention also ameliorated axonal degeneration and normalized motor functions. Moreover, in a paradigm of adult remyelination, ketogenic diet facilitated repair and attenuated axon damage. We suggest that a therapy with lipids such as ketone bodies, that readily enter the brain, can circumvent the requirement of a disrupted blood–brain barrier in the treatment of myelin disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00401-019-01985-2) contains supplementary material, which is available to authorized users.